AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24517052
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine anti‐rheumatic treatment: Methotrexate 10 mg/week; Diclofenac 50 mg twice daily when pain was obvious)
Trial: 16638738
Drug: BAY 59-7939
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 59-7939 (rivaroxaban) 5 mg tablets (fasted and fed)
Trial: 16638738
Drug: BAY 59-7939
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 59-7939 (rivaroxaban) 10 mg
Trial: 16638738
Drug: BAY 59-7939
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 59-7939 (rivaroxaban) 20 mg
Trial: 16638738
Drug: BAY 59-7939
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 59-7939 (rivaroxaban) with ranitidine (150 mg twice daily)
Trial: 16638738
Drug: BAY 59-7939
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 59-7939 (rivaroxaban) with antacid (10 mL)
Trial: 15598997
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A - initial conservative treatment followed by interval appendectomy six weeks later
Trial: 15598997
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C - conservative treatment alone
Trial: 9709410
Drug: Substance P
RxNorm normalized name: Substance P
DrugBank: Substance P (DB19198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance P (2-8 pmol/min) with L-NMMA (1-4 micrograms/min)
Trial: 9709410
Drug: L-NMMA (1-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (1-4 micrograms/min) alone
Trial: 2919798
Drug: Potassium metabisulfite
RxNorm normalized name: Potassium Metabisulfite
DrugBank: Potassium metabisulfite (DB15841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium metabisulfite oral aqueous challenge
Trial: 16329464
Drug: cis-9,trans-11 CLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cis-9,trans-11 CLA (3 g/day)
Trial: 16329464
Drug: trans-10,cis-12 CLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trans-10,cis-12 CLA (3 g/day)
Trial: 12410740
Drug: Nocturia (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nocturia (mean of twice or more/night)
Trial: 12410740
Drug: Age, poor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age, poor health status, and use of medication
Trial: 10421262
Drug: Postoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiotherapy at a total dose of 60 gray
Trial: 7669462
Drug: Interscalene brachial
RxNorm normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interscalene brachial plexus block with 0.5% bupivacaine and adrenaline 1/200,000 40 ml with the addition of morphine 5 mg
Trial: 7669462
Drug: Interscalene brachial
RxNorm normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interscalene brachial plexus block with 0.5% bupivacaine and adrenaline 1/200,000 40 ml alone
Trial: 2401752
Drug: Ticlopidine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (250 mg) administered after food
Trial: 2401752
Drug: Ticlopidine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (250 mg) administered after antacid
Trial: 2401752
Drug: Ticlopidine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (250 mg) administered in fasting conditions
Trial: 7434079
Drug: Quinacrine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinacrine (100 mg t.i.d. for 5 days)
Trial: 7434079
Drug: Metronidazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (200 mg t.i.d. for 7 days)
Trial: 7434079
Drug: Metronidazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (2 gm single dose)
Trial: 7434079
Drug: Tinidazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole (2 gm single dose)
Trial: 7434079
Drug: Ornidazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornidazole (2 gm single dose)
Trial: 6134959
Drug: Ceftriaxone 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 125 mg IM
Trial: 23639952
Drug: Group music
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group music therapy (12 sessions, two 30-min sessions per week for 6 weeks)
Trial: 22495183
Drug: Oxycodone 5
RxNorm normalized name: oxycodone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 5 mg/70 kg
Trial: 22495183
Drug: Oxycodone 20
RxNorm normalized name: oxycodone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 20 mg/70 kg
Trial: 22495183
Drug: Oxycodone (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (daily administration)
Trial: 22495183
Drug: Oxycodone (intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (intermittent administration)
Trial: 22495183
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily administration)
Trial: 16416004
Drug: Interferon-alpha alone
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha alone for 1 month followed by 5 months of continuous treatment with interferon-alpha (treatment group A)
Trial: 16416004
Drug: Interferon-alpha combined
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha combined with thymosin-alpha1 for 1 month followed by 5 months of continuous treatment with interferon-alpha and thymosin-alpha1 (treatment group B)
Trial: 16416004
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antiviral drug after lamivudine withdrawal)
Trial: 31177984
Drug: Posterior limb
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior limb internal capsule involvement
Trial: 31177984
Drug: Anterior limb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior limb internal capsule involvement
Trial: 31177984
Drug: Anterior limb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior limb internal capsule lesions
Trial: 23728047
Drug: Controller medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controller medicine
Trial: 27914817
Drug: Quick relief
RxNorm normalized name: Capzasin Quick Relief
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quick relief medicine
Trial: 27914817
Drug: Parental help
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parental help with medications
Trial: 27914817
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of medications
Trial: 26435363
Drug: Daylight photodynamic
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daylight photodynamic therapy (DL‐PDT) with methyl aminolevulinate (MAL)
Trial: 26435363
Drug: Conventional photodynamic
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional photodynamic therapy (c‐PDT) with methyl aminolevulinate (MAL)
Trial: 19608845
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection (Group S): 30 mL of mepivacaine 1.5% injected posterior to the axillary artery
Trial: 19608845
Drug: Triple injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple injections (Group T): 10 mL of mepivacaine 1.5% injected on the posterior, medial, and lateral aspects of the axillary artery
Trial: 16448828
Drug: Placebo ultrasound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ultrasound treatment (inactivated device, 10 sessions of physiotherapy of 20 min each)
Trial: 2286709
Drug: Haloperidol (fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (fixed doses to achieve plasma levels above and below 18 ng/ml)
Trial: 7028259
Drug: Initial low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Initial low-dose single-agent CCNU (CAMP postponed)
Trial: 31998998
Drug: Expected treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expected treatment outcomes with knowledge of covariates
Trial: 30176834
Drug: 30-min vigorous-intensity
RxNorm normalized name: California intense cedar pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-min vigorous-intensity aerobic exercise session 24 hours prior to each anthracycline treatment
Trial: 30176834
Drug: Prepared diet
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prepared diet reduced to 50% of caloric needs for 48 hours prior to each anthracycline treatment
Trial: 24508349
Drug: Elevated glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated glucose (>7.8 mmol/L)
Trial: 19947986
Drug: Increased nocturnal
RxNorm normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Increased nocturnal oxygen flow rate (1 L more oxygen)
Trial: 18762517
Drug: Cooling treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooling treatment
Trial: 10901709
Drug: Ifetroban (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifetroban (3 mg/kg in rats)
Trial: 10901709
Drug: Ifetroban (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifetroban (1 mg/kg in dogs)
Trial: 10901709
Drug: Ifetroban (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifetroban (1 mg/kg in monkeys)
Trial: 10901709
Drug: Ifetroban (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifetroban (50 mg in humans)
Trial: 12186623
Drug: One-week quadruple
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-week quadruple therapy (bismuth-based triple therapy plus a PPI or histamine receptor 2-blocker)
Trial: 12186623
Drug: Furazolidone-based triple
RxNorm normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furazolidone-based triple therapy (furazolidone plus an antibiotic and a bismuth salt, a PPI or RBC)
Trial: 12186623
Drug: Fluoroquinolone-based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoroquinolone-based triple therapy (levofloxacin or moxifloxacin plus an antibiotic and a PPI)
Trial: 12186623
Drug: Ecabet sodium-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ecabet sodium-based triple therapy (ecabet plus two antibiotics)
Trial: 12186623
Drug: Rifabutin in
RxNorm normalized name: Product containing rifabutin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifabutin in combination with a PPI and amoxycillin
Trial: 16021868
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor (PI) regimen
Trial: 8924308
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide with EMLA cream
Trial: 8924308
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide with intradermal lidocaine
Trial: 7523772
Drug: Cilazapril 5
RxNorm normalized name: cilazapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 5 mg b.i.d.
Trial: 25273893
Drug: Active T-PEMF
RxNorm normalized name: t-plasminogen activator
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active T-PEMF (one daily dose)
Trial: 25273893
Drug: Active T-PEMF
RxNorm normalized name: t-plasminogen activator
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active T-PEMF (two daily doses)
Trial: 25273893
Drug: Placebo T-PEMF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo T-PEMF (one daily dose)
Trial: 24384592
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral tenofovir (TDF) and emtricitabine/tenofovir (FTC/TDF) PrEP
Trial: 17014550
Drug: High-volume haemofiltration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume haemofiltration (HVHF) at 6 L/h
Trial: 17014550
Drug: Continuous venovenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous venovenous haemofiltration (CVVH) at 2 L/h
Trial: 11020900
Drug: Gabexate mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabexate mesilate infusion at a dose of 100 mg/hr for 7 days
Trial: 9540058
Drug: Oral tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tamoxifen (TAM) at doses of 40, 80 or 120 mg/day
Trial: 9540058
Drug: Surgery, radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery, radiotherapy (4500-6000 cGy), and carboplatin (CBDCA; dose of 450-600 mg/m2)
Trial: 7800587
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (12 grams daily, 3.6 g of EPA and DHA) for 3 weeks
Trial: 7800587
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (12 grams daily) for 3 weeks
Trial: 7800587
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (12 grams daily) for 6 weeks (in 9 patients)
Trial: 3388151
Drug: Diltiazem (DTZ)
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem (DTZ) 90 mg twice daily, increased to 180 mg if non-responders after 8 weeks
Trial: 3388151
Drug: Hydrochlorothiazide (HCT)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCT) 25 mg once daily, increased to 50 mg if non-responders after 8 weeks
Trial: 29311135
Drug: BMS‐823778 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐823778 (single and multiple ascending doses)
Trial: 29311135
Drug: BMS‐823778 (pharmacokinetics)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐823778 (pharmacokinetics)
Trial: 22723267
Drug: rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rosiglitazone (RSG) 4 mg b.i.d
Trial: 10204379
Drug: Acupuncture treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatments in addition to non-steroidal anti-inflammatory drugs and intraarticular administration of glucocorticosteroids and inhibitors of proteases
Trial: 10204379
Drug: Non-steroidal anti-inflammatory
RxNorm normalized name: Non-steroidal anti-inflammatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drugs together with intraarticular administration of glucocorticosteroids and inhibitors of proteases
Trial: 28095046
Drug: Daily vitamin
RxNorm normalized name: Daily Vitamin Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily vitamin D3 1,800 IU
Trial: 25524395
Drug: Time framed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time framed as dates (e.g., June 1st, 2015)
Trial: 25524395
Drug: Time framed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time framed as days (e.g., 5000 days)
Trial: 23748948
Drug: Silver zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver zinc sulfadiazine with added sericin cream
Trial: 23748948
Drug: Silver zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver zinc sulfadiazine cream (control)
Trial: 21880194
Drug: bovine lactoferrin
RxNorm normalized name: Bovine lactoferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bovine lactoferrin (bLF) 70 mg/day
Trial: 17845952
Drug: Clinical pathway
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical pathway for managing UTIs in LTCFs, including decision tools for urine culture and antibiotic treatment initiation.
Trial: 9533468
Drug: Cefixime suspension
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefixime suspension 8 mg/kg/day bd for 10 days
Trial: 9533468
Drug: Co-amoxiclav suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav suspension 80 mg/kg/day tds for 10 days
Trial: 7914121
Drug: Proxodolol 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proxodolol 40 mg
Trial: 7914121
Drug: Proxodolol 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proxodolol 80 mg
Trial: 620480
Drug: Cyproheptadine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproheptadine (up to 42 mg/day)
Trial: 28919011
Drug: Dabrafenib plus
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib plus trametinib (oral dabrafenib 150 mg twice per day plus oral trametinib 2 mg once per day)
Trial: 25553889
Drug: Brodalumab 140
RxNorm normalized name: brodalumab 140 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodalumab 140 mg every 2 weeks
Trial: 25553889
Drug: Brodalumab (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodalumab (doses unspecified)
Trial: 22267018
Drug: Oral tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral tenofovir and emtricitabine/tenofovir PrEP
Trial: 2652168
Drug: Cocaine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (40 mg) with haloperidol (8 mg) pretreatment
Trial: 2652168
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with haloperidol (8 mg) pretreatment
Trial: 2652168
Drug: Cocaine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (40 mg) with placebo pretreatment
Trial: 728284
Drug: Intravenous disopyramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous disopyramide (2 mg/kg)
Trial: 728284
Drug: Oral disopyramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral disopyramide (Rythmodan and Norpace, 300 mg)
Trial: 22167437
Drug: Intravenous sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sedation with local anesthesia (sedation group, n = 123)
Trial: 19209092
Drug: Hexavalent vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexavalent vaccine
Trial: 15320685
Drug: Hormonal responses
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal responses (testosterone, sex hormone binding globulin, free androgen index)
Trial: 9031463
Drug: RO-11 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO-11 at a dose of 7,500 anti-FXa i.u. (110 anti-FXa i.u./Kg)
Trial: 9031463
Drug: RO-11 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO-11 at doses of 9,000 and 12,500 anti-FXa i.u.
Trial: 9031463
Drug: RO-11 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO-11 (all doses)
Trial: 8034236
Drug: Heparin (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (calcium heparin, 12,500 IU in 0.5 ml)
Trial: 31352853
Drug: SQ tree
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ tree sublingual immunotherapy (SLIT)-tablet
Trial: 30279504
Drug: Atorvastatin 10mg/fenofibric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10mg/fenofibric acid 135mg for 12 weeks
Trial: 30279504
Drug: Atorvastatin 20mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20mg for 12 weeks
Trial: 18521047
Drug: Unopposed estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unopposed estrogen (conjugated estrogens 0.625 mg)
Trial: 18521047
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus 2.5 mg of medroxyprogesterone acetate
Trial: 7586303
Drug: Sulotroban (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulotroban (800 mg QID)
Trial: 1425867
Drug: Theophylline (Th)
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline (Th) 450-900 mg in the evening
Trial: 2253659
Drug: Terbutaline (Te)
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terbutaline (Te) 7.5 mg twice daily
Trial: 28809989
Drug: Calcipotriene 0.005%
RxNorm normalized name: CALCIPOTRIENE 0.005% OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% topical suspension (Taclonex® TS)
Trial: 28809989
Drug: Betamethasone Dipropionate
RxNorm normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone Dipropionate 0.05% lotion (Diprosone®)
Trial: 22537100
Drug: OROS hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS hydromorphone ER 16 mg
Trial: 10550565
Drug: Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation B (test formulation)